FDA delays decision on Risperdal Consta to treat bipolar disorder

02/10/2009 | Bloomberg · Forbes

Seeking more information, the FDA postponed its decision on the use of Johnson & Johnson's Risperdal Consta to treat frequent mood swings in patients with bipolar disorder. The product received FDA clearance in 2003 as a twice-a-month treatment for schizophrenia.

View Full Article in:

Bloomberg · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA